Search clinical trials for: M9241

Total 10 results

National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma

Colorectal Neoplasms | Colorectal Cancer | Cholangiocarcinoma | Bile Duct Cancer | Bile Duct Neoplasms | Metastatic Colorectal Cancer (Mcrc) | Intrahepatic Cholangiocarcinoma (Icc) | Intrahepatic Bile Duct Cancer

United States
EMD Serono Research & Development Institute, Inc.
Merck KGaA, Darmstadt, Germany

Terminated

A Phase Ib Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Avelumab in Combination With M9241(NHS-IL12) (JAVELIN IL-12) (COMBO)

Advanced Solid Tumors

Spain, United States, Netherlands, Hungary, Italy, France, Belgium
National Cancer Institute (NCI)

Recruiting

T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine M9241 in Localized High- and Intermediate-Risk Prostate Cancer Treated With Androgen Deprivation Therapy

Cancer Of Prostate

United States
M.D. Anderson Cancer Center

Withdrawn

Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | Hormone Receptor Positive Breast Adenocarcinoma | Metastatic HER2 Negative Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Terminated

Immune Checkpoint Inhibitor M7824 and the Immunocytokine M9241 in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Advanced Pancreas Cancer

Pancreatic Neoplasms | Pancreatic Cancer | Metastatic Pancreatic Cancer | Histologically or Cytologically Confirmed Pancreatic Cancer | Unresectable or Borderline Resectable Pancreatic Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Phase II Trial of Combination Immunotherapy in Subjects With Advanced Small Bowel and Colorectal Cancers

Small Bowel Cancers | Colorectal Cancers

United States
National Cancer Institute (NCI)

Recruiting

Enzalutamide and M9241 in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

Recurrent Prostate Cancer | Prostate Cancer | PET Positive

United States
National Cancer Institute (NCI)

Recruiting

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

Cancer Of Prostate | Prostate Neoplasms

United States
National Cancer Institute (NCI)

Recruiting

Bintrafusp Alfa (M7824) and NHS-IL12 (M9241) Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies

Urogenital Neoplasms | Bladder Cancer | Urothelial Cancer | Genitourinary Cancer | Urogenital Cancer

United States
National Cancer Institute (NCI)

Recruiting

A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers

Cervical Cancer | Vulvar Cancer | Colon Cancer | Anal Cancer | Vaginal Cancer | Oropharyngeal Cancer | Penile Cancer | HPV | Human Papillomavirus | Neck Cancer

United States

Search clinical trials for: M9241

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Liberia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations